When did sprycel go generic?

Sprycel (dasatinib) is not currently generic. The drug is protected by patents, and as of now, no generic versions have been approved by the U.S. Food and Drug Administration (FDA). [1]

When are Sprycel's patents expected to expire?

The patent landscape for Sprycel is complex and involves multiple patents. Some sources indicate that the main patents for Sprycel could expire around 2026 or later, depending on patent litigation outcomes and other factors. [2] DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for pharmaceuticals like Sprycel. [3]

Can biosimilars be developed for Sprycel?

Sprycel is a small molecule drug, not a biologic. Therefore, the development pathway for generic versions is through demonstrating bioequivalence, not through the biosimilar pathway, which is for biologic drugs. [4]

Who manufactures Sprycel?

Sprycel is manufactured by Bristol Myers Squibb. [5]

What is Sprycel used for?

Sprycel is a tyrosine kinase inhibitor used to treat certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). [6]